GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases

In this comparative effectiveness research study of 12 245 patients with CD, treated with tumor necrosis factor-α antagonists, vedolizumab, ustekinumab, risankizumab, or upadacitinib and followed up over a mean 27 months, no clinically meaningful differences in the risk of key safety events, including serious infections, venous thromboembolism, and major adverse cardiovascular events, were found.